ReShape Lifesciences™ is a medical device company focused on technologies to treat obesity and metabolic diseases. The FDA-approved LAP-BAND® Adjustable Gastric Banding System is designed to provide minimally invasive long-term treatment of severe obesity and is an alternative to more invasive surgical stapling procedures such as the gastric bypass or sleeve gastrectomy. The ReShape Vest™ System is an investigational, minimally invasive, laparoscopically implanted medical device that wraps around the stomach, emulating the gastric volume reduction effect of conventional weight-loss surgery, and is intended to enable rapid weight loss in obese and morbidly obese patients without permanently changing patient anatomy.
Company profile
Website
CEO
Barton P. Bandy
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Medtronic • Varian Medical Systems • Conmed • Integer • Masimo • Natus Medical • LivaNova • BioPlus Acquisition • QT Imaging • Outset Medical ...
Former names
EnteroMedics Inc
SEC CIK
Corporate docs
Subsidiaries
ReShape Lifesciences Netherlands B.V. • ReShape Lifesciences Australia Pty Ltd • ReShape Costa Rica Sociedad de Responsabilidad Limited ...
Latest filings (excl ownership)
EFFECT
Notice of effectiveness
28 Jun 21
EFFECT
Notice of effectiveness
28 Jun 21
EFFECT
Notice of effectiveness
28 Jun 21
EFFECT
Notice of effectiveness
28 Jun 21
EFFECT
Notice of effectiveness
28 Jun 21
EFFECT
Notice of effectiveness
28 Jun 21
EFFECT
Notice of effectiveness
28 Jun 21
EFFECT
Notice of effectiveness
28 Jun 21
EFFECT
Notice of effectiveness
28 Jun 21
EFFECT
Notice of effectiveness
28 Jun 21
Transcripts
Earnings call transcript
2022 Q1
23 May 22
Earnings call transcript
2021 Q4
29 Mar 22
Earnings call transcript
2021 Q3
13 Nov 21
Earnings call transcript
2019 Q3
14 Nov 19
Earnings call transcript
2019 Q2
14 Aug 19
Earnings call transcript
2019 Q1
20 May 19
Earnings call transcript
2018 Q4
1 Apr 19
Earnings call transcript
2018 Q3
14 Nov 18
Earnings call transcript
2018 Q2
16 Aug 18
Earnings call transcript
2017 Q4
2 Apr 18
Financial summary
Quarter (USD) | Mar 21 | Dec 20 | Sep 20 | Jun 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 20 | Dec 19 | Dec 18 | Dec 17 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 1.95 mm | 1.95 mm | 1.95 mm | 1.95 mm | 1.95 mm | 1.95 mm |
Cash burn (monthly) | 353.67 k | 18.42 k | 1.62 mm | 1.86 mm | 653.67 k | 605.50 k |
Cash used (since last report) | 13.03 mm | 678.67 k | 59.56 mm | 68.57 mm | 24.09 mm | 22.31 mm |
Cash remaining | -11.09 mm | 1.27 mm | -57.62 mm | -66.63 mm | -22.14 mm | -20.37 mm |
Runway (months of cash) | -31.3 | 68.8 | -35.6 | -35.8 | -33.9 | -33.6 |
Institutional ownership, Q3 2021
13F holders | Current |
---|---|
Total holders | 0 |
Opened positions | 0 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 0.00 |
Total shares | 0.00 |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|